Industries > Pharma > Cancer Biologics Therapies Market Report 2021-2031

Cancer Biologics Therapies Market Report 2021-2031

Forecasts by Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), by Product (Monoclonal Antibodies, Cytokines, Cancer Growth Blockers, Vaccines, Blood Cell Growth Factors, and Others), by Indication (Breast Cancer, Cervical Cancer, Colon and Rectal Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Renal Cell Cancer, Melanoma), by Biologic Drugs (Bevacizumab, Trastuzumab, Trastuzumab Emtansine, Pertuzumab, Rituximab, Cetuximab, Panitumumab, Ramucirumab, Necitumumab, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Ipilimumab), by End-user (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cancer Biologics Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 01 April 2021
PAGES: 478
PRODUCT CODE: PHA1122
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA1122 Categories: , Tags: , ,

This report is intended to provide an in-depth analysis of the latest trends prevailing in the cancer biologics therapy market and its growth and development in the next decade. The changing demographics of the world population, increasing cancer prevalence, developing healthcare infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.

Cancer Biologics Therapy Market: Regional Landscape
Presence of well-established healthcare infrastructure and biopharmaceutical companies are expected to further strengthen North America cancer biologics therapy market in coming years. Increasing government initiatives to strengthen healthcare industry, rising prevalence of chronic diseases, followed by increasing healthcare expenditure in emerging economies are expected to drive Asia Pacific cancer biologics therapy market over the forecast period.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

What are the Market Driving Factors?
• Rising Cancer Prevalence Worldwide
• Increasing Ageing Population in Developed as well as Developing Economies

Key Challenges for Cancer Biologics Therapy Market
• Shortage of Skilled Workforce in the Biopharmaceutical Industry
• High Cost Associated with Biopharmaceutical Drug Manufacturing

What are the Market Opportunities?
• Increasing R&D Spending of Biopharmaceutical Companies
• Future Perspective in Oncology Industry

Why you Should buy this Report?
Apart from market estimation and forecast to 2031 the report covers below mentioned important factors to offer in-depth analysis of cancer biologics industry
• SWOT Analysis
• Porter’s Five Forces Model
• Oncology Market Trends
• Global Oncology Spending, 2016 – 2031
• Disease Prevalence and Incidence in Europe by Country
• EMA Approved Biologics in Oncology
• Biosimilars and R&D Biologics in Development

What are the Leading Companies Operating in the Market?
• AbbVie Inc
• F.Hoffman La Roche
• GlaxoSmithKline
• Eli Lilly and Company
• Amgen
• Johnson & Johnson
• Merck & Co.
• Pfizer
• Agilent Technologies, Inc.
• Bio-Rad Laboratories
• GE Healthcare
• Illumina
• Qiagen N.V.
• Biocept
• Guardant Health

CTA

Market Segmentation and Scope

Cancer Biologics Therapy Market by Treatment
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Others

Cancer Biologics Therapy Market by Indication
• Breast cancer
• Cervical cancer
• Colon and rectal cancer
• Gastric cancer
• Lung cancer
• Ovarian cancer
• Renal cell cancer
• Melanoma

Cancer Biologics Therapy Market by Biologic Drug
• Bevacizumab
• Trastuzumab
• Trastuzumab emtansine
• Pertuzumab
• Rituximab
• Cetuximab
• Panitumumab
• Ramucirumab
• Necitumumab
• Pembrolizumab
• Atezolizumab
• Durvalumab
• Nivolumab
• Ipilimumab

Cancer Biologics Therapy Market by End User
• Hospitals
• Specialty Clinics
• Cancer and Radiation Therapy Centers

Cancer Biologics Therapy Market by Product
• Monoclonal Antibodies
• Cytokines
• Cancer Growth Blockers
• Vaccines
• Blood Cell Growth Factors
• Others

Cancer Biologics Therapy Market by Region

• North America Cancer Biologics Therapy Market
• U.S. Cancer Biologics Therapy Market
• Canada Cancer Biologics Therapy Market

• Europe Cancer Biologics Therapy Market
• UK Cancer Biologics Therapy Market
• Germany Cancer Biologics Therapy Market
• France Cancer Biologics Therapy Market
• Italy Cancer Biologics Therapy Market
• Spain Cancer Biologics Therapy Market
• Portugal Cancer Biologics Therapy Market
• Poland Cancer Biologics Therapy Market
• Hungary Cancer Biologics Therapy Market
• Czech Republic Cancer Biologics Therapy Market
• Slovakia Cancer Biologics Therapy Market
• Slovenia Cancer Biologics Therapy Market
• Romania Cancer Biologics Therapy Market
• Bulgaria Cancer Biologics Therapy Market
• Croatia Cancer Biologics Therapy Market
• Baltic States Cancer Biologics Therapy Market
• Serbia Cancer Biologics Therapy Market

• Asia Pacific Cancer Biologics Therapy Market
• China Cancer Biologics Therapy Market
• Japan Cancer Biologics Therapy Market
• India Cancer Biologics Therapy Market
• Australia Cancer Biologics Therapy Market
• South Korea Cancer Biologics Therapy Market
• Rest of Asia Pacific Cancer Biologics Therapy Market

• Latin America Cancer Biologics Therapy Market
• Brazil Cancer Biologics Therapy Market
• Mexico Cancer Biologics Therapy Market
• Argentina Cancer Biologics Therapy Market
• Rest of Latin America Cancer Biologics Therapy Market

• Middle East & Africa Cancer Biologics Therapy Market
• South Africa Cancer Biologics Therapy Market
• GCC Cancer Biologics Therapy Market
• Rest of Middle East & Africa Cancer Biologics Therapy Market

Cancer Biologics Therapies Market Report 2021-2031
Need industry data? Please contact us today.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Cancer Biologics Therapies Market and leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Cancer Biologics Therapies Market Report 2021-2031: Forecasts by Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), by Product (Monoclonal Antibodies, Cytokines, Cancer Growth Blockers, Vaccines, Blood Cell Growth Factors, and Others), by Indication (Breast Cancer, Cervical Cancer, Colon and Rectal Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Renal Cell Cancer, Melanoma), by Biologic Drugs (Bevacizumab, Trastuzumab, Trastuzumab Emtansine, Pertuzumab, Rituximab, Cetuximab, Panitumumab, Ramucirumab, Necitumumab, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Ipilimumab), by End-user (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cancer Biologics Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Cancer Biologics Therapies Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Cancer Biologics Therapies Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories